


Characterization of Glycolytic Enzymes and Pyruvate Kinase M2 in Type 1 and 2 Diabetic Nephropathy

Diabetes Care. 2019; <https://doi.org/10.2337/dc18-2585>





<https://twitter.com/i/moments/1057661851759230978>



- Concentrations of glycolytic enzymes and metabolites altered in diabetic patients (T2DM/T1DM) with CKD




Study Aim: Use proteomics and metabolomics to identify biomarkers that are significantly altered in various states of renal dysfunction

Part 1: assaying various glycolytic enzymes in post-mortem kidneys (39) of various diabetic states



Part 2: measuring concentrations of glycolytic enzymes (1129) and metabolites (58) in the plasma

Medalist Study



Pyruvate, a metabolite of PKM2, was also upregulated in patients with normal kidney function



- Many enzymes & metabolites significantly altered in CKD, DM, and DM + CKD
- PKM2 = one of many promising biomarkers of DM and CKD → ± earlier detection and offer new therapeutic targets



Medscape

@Medscape



@nephondemand

Learn about this and other markers of diabetic kidney disease at <https://datastudio.google.com/s/rLkMdVQfrBI>